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SYSTEMS OF ZYMOGEN ACTIVATION**
During the thirties, Northrop, Kunitz and their co-workers gave to the
world a set of crystallized enzymes and zymogens.1. They also conveyed a
set of corresponding ideas: that certain proteolytic enzymes are produced
by the body in precursor form, that these precursors can be activated by
slight proteolysis, and that this process is usually catalyzed by enzymes.
Moreover, they delineated a system in which certain enzymes have the
function of activating the precursors of other enzymes. In this classic
system, the process is initiated when the enterokinase of the intestine be-
gins to activate the trypsinogen of the pancreatic secretion. The resulting
trypsin then activates more of the trypsinogen, as well as the other zymo-
gens of the pancreatic secretion, chymotrypsinogen and procarboxypeptidase.
Here, there are two activator-enzymes: enterokinase, (now also called
enteropeptidase), and trypsin; and the first can activate the precursor of
the second. Other systems might have more such factors, activatable in
parallel or in series. How long such a series might be is suggested by
recent theories of blood coagulation.`~'
It now seems appropriate to state explicity what has long been assumed-
that there are basic similarities in various systems that have the common
feature of zymogen activation. This one aspect of formal resemblance in-
vites attention to the biochemical amplification' which accrues when an
enzyme hastens the production of another enzyme. It also brings into focus
questions of common mechanisms, such as the splitting of certain peptide
bonds. These questions, in turn, lead to consideration of how far substitu-
tions between systems, or even shared pathways might be possible, at least
experimentally, and perhaps spontaneously in health or disease. Some prog-
ress along these lines has already been made.
When crystallized trypsin became available, Eagle and Harris showed
that it could activate partially purified prothrombin.' The converse pro-
cedure, in which a clotting factor was tested on precursors from the pan-
creas, was described in this Journal, in 1954, with negative results.7 This
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enquiry however, dealt with lipoid thromboplastin as possible cofactor for
trypsin. More recently, activation of zymogens from the pancreas by en-
zymes from the blood has become of interest."~
Thrombokinase is an enzyme obtainable from blood plasma, and defined
by its capacity to activate prothrombin.' It was first isolated in a form
approaching homogeneity in 1960.17 Since then others, starting with different
definitions, have arrived at potent preparations of activated factor X18 and
autoprothrombin C,19 both of which may be essentially the same as throm-
bokinase. One important feature shared by these differently named, but
possibly identical factors, is that their physiologic role is thought to be
activation of a zymogen.
Not only does thrombokinase activate prothrombin; it can also activate
chymotrypsinogen, as shown in Figure 1. A constant amount of crystallized
chymotrypsinogen A was incubated with different amounts of thrombo-
kinase. At intervals, samples were taken from each mixture and assayed
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FIG. 1. Activation of chymotrypsinogen by different concentrations of thrombokinase.
Each activation test is represented by a curve, which was followed for 120 minutes.
Chymotrypsin activity was estimated by the rate of increase in optical density of an
enzyme-substrate mixture, and plotted as thousandths of a density unit per minute. See
text. Figure reproduced from Reference 10, with permission.
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with benzoyl-tyrosine ethyl ester. This substrate is hydrolyzed by chymo-
trypsin but not by thrombokinase. Hydrolysis is accompanied by an in-
crease in optical density at 256 mju.; and the rate of increase per minute
has been plotted as a direct measure of chymotrypsin activity. Chymotrypsin
activity increased progressively; and the slope of increase was determined
by the amount of thrombokinase.
In this experiment, the amount of thrombokinase exceeded the amount
of chymotrypsinogen. However, it was soon found that chymotrypsin was
produced about as fast when thrombokinase was reduced tenfold and the
chymotrypsinogen was simultaneously increased tenfold. This is shown in
Figure 2, where the concentration of chymotrypsinogen was 2 mg. per
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FIG. 2. Relation of chymotrypsin produced in one hour to concentration of throm-
bokinase used as activator of chymotrypsinogen. Here, each activation test is repre-
sented by a single point. Chymotrypsin activity was estimated by the rate of increase
in optical density of an enzyme-substrate mixture, and plotted as thousandths of a
density unit per minute. Figure reproduced from Reference 14, with permission.
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ml. in all experiments. Activations were performed with different amounts
of thrombokinase, ranging from 0.2 mg. down to 0.025 mg/ml. Esterolytic
assays were performed as before, but on samples taken at one minute and
61 minutes. The difference between these two assays was a measure of
the chymotrypsin produced in one hour: and this difference, in terms of
esterolytic activity, is now indicated by the scale on the left. The plotted
values show that the amount of chymotrypsin produced in one hour was
proportional to the amount of thrombokinase used as activator.
A unit of chymotrypsinogen activator was then defined in terms of the
numbers on the ordinate scale of Figure 2. This made it convenient to assay
for chymotrypsinogen activator at successive stages in the purification of
thrombokinase. Some results with the active fractions are shown in Table
1, together with the thrombin titers of the same preparations. Thrombin
was progressively eliminated during the purification of thrombokinase,
whereas the activator was not. As a result, the ratio of chymotrypsinogen
activator to thrombin was more than 2,000 times as great at step 8 as it was
at step 5. This does not necessarily mean that thrombin cannot activate
chymotrypsinogen; but it does mean that the chymotrypsinogen activator
that we have been following is not thrombin.
TABLE 1. SEPARATION OF CHYMOTRYPSINOGEN ACTIVATOR FROM THROMBIN.*
Step of Thrombokinase Chymotrypsinogen Chymotrypsinogen
Preparation activator Thrombin activator
Thrombin.
u/ml u/mi ratio
5. Activated concentrate 402 980 0.41
6. Redissolved iso. 117 31 3.8
electric ppt.
7. Chromatographic fraction 630 4.7 134
8. Electrophoretic fraction 784 0.81 968
*Reproduced from Reference 14, with permission.
However, it may well be thrombokinase. If due allowance is made for the
limitations of present assays, other data have shown that the chymotryp-
sinogen activator was purified along with thrombokinase from step 5
through step 8. This parallelism was shown in another way by taking some
incompletely purified thrombokinase, at step 7, and putting it through a
column of Sephadex G-200. Figure 3, in chart B, shows that most of the
protein emerged from the column in a position corresponding to the third
peak of serum proteins, shown in the upper chart, A. Activity tests done on
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the subfractions revealed that the capacity to activate chymotrypsinogen
paralleled the capacity to activate prothrombin. This was true whether
prothrombin was activated by the subfractions alone, in the presence of
oxalate, as shown by the triangles in chart B, or whether it was activated
with the help of calcium ions, phospholipid and accelerator globulin, as
shown by the dots.
Chart A depicts a preliminary run on the same column, done with barium
carbonate-treated bovine serum. Accelerator globulin activity was found in
the first two peaks of serum protein, in accord with the observations of
others.
At best, thrombokinase is a poor activator of chymotrypsinogen, having
less effect than one hundredth as much trypsin. But thrombokinase does
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FIG. 3. Gel filtration on a column of Sephadex G-200. A. Barium carbonate-treated
bovine serum. B. Step-7 thrombokinase. CHTG,-chymotrypsinogen. Reproduced from
Reference 11, with permission.
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not owe its effect to a trace contamination by trypsin. Like trypsin, throm-
bokinase is susceptible to soybean trypsin inhibitor; but unlike trypsin,
it is not sensitive to Kunitz's pancreatic inhibitor. In fact, thrombokinase
can activate chymotrypsinogen in the presence of pancreatic trypsin in-
hibitor. In such cases, the addition of trypsin and trypsinogen makes no
difference; and this further indicates that thrombokinase acts directly on
chymotrypsinogen, without the mediation of trypsinogen-to-trypsin conver-
sion. Even without added inhibitor, it is unlikely that activation depends
on a trypsinogen contaminant in the chymotrypsinogen; for thrombokinase
activated 9X crystallized chymotrypsinogen as fast as 5X crystallized
chymotrypsinogen.
While it is now reasonably certain that thrombokinase can activate
chymotrypsinogen, there is still no denying that the process is slow. But
this is not supposed to be a physiologic function of thrombokinase. What
is more worrisome is that thrombokinase is not really a good activator of
prothrombin, unless it is accompanied by calcium, phospholipid and ac-
celerator globulin. This has led many to suspect that the true function of
our thrombokinase is to convert accelerator globulin into an enzyme that
then activates prothrombin. A similar conception of factor V, (or accelera-
tor globulin), was first challenged 20 years ago by Ware, Murphy, and
Seegers.' Since then, it has not been proven that accelerator globulin is a
zymogen; nor has it been shown that any derivative of accelerator globulin
can, by itself, activate prothrombin. But 20 years of negatives do not make
us positive; and it is wise to leave this question open. Meanwhile, it be-
hooves us to contemplate the possibility that, while our thrombokinase is
able to activate prothrombin, its true physiologic role may be to activate
something else. To put it bluntly, it is conceivable that we have isolated
the wrong prothrombin activator.
In the face of this terrifying prospect, we can take some comfort in the
fact that thrombokinase, activated factor X and autoprothrombin C appear
to be essentially one and the same enzyme; and if so, it is the only pro-
thrombin-activating enzyme isolated from blood, so far. But then, we have
to consider that this enzymatic activation seems to have three different
accessory factors; calcium, phospholipid, and accelerator globulin. Such a
relationship may have no precedent; and it is exciting to think that we may
be contributing something new to the science of biochemistry. On the other
hand, we must admit that while the accumulated data favor the view that
accelerator globulin (factor V) is an accessory factor, "` we really don't
know the mechanism of its action.
We do know that thrombokinase is an enzyme, as first demonstrated by
its action on tosylarginine methyl ester.1 Since then, Sherry, Alkjaersig,
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and Fletcher have found that thrombokinase hydrolyzed their substituted
arginine esters faster than their substituted lysine esters.'2 This is of
particular interest because the primary event in the activation of chymo-
trypsinogen by trypsin is the hydrolysis of an arginyl-isoleucine bond.'
And perhaps this bond is also hydrolyzed by thrombokinase.
In contrast, the activation of trypsinogen involves the hydrolysis of a
lysyl-isoleucine bond.' Plasmin, (or fibrinolysin), is known to hydrolyze
lysine esters.' If it is correct that plasmin can activate its own precursor,'
this at least shows that plasmin can exert an activator effect, regardless
of which bond is broken. It has now been found that plasmin can activate
trypsinogen.'
Until recently, this would have been a forbidding venture; because tryp-
sinogen preparations often contain enough trypsin to set off the autocatalytic
activation. But now, the work of Balls' has made available crystallized
trypsinogen with less than one per cent of its potential in the active form.
Such trypsinogen, at 200 jug per ml., is dilute enough to limit autocatalytic
complications, yet concentrated enough for a sensitive test.
It soon appeared that activation of trypsinogen was influenced differently
by calcium, depending on whether the activator was trypsin or plasmin.
For one experiment of Figure 4, trypsinogen was activated by added trypsin
in the presence of different amounts of calcium chloride. The highest activa-
tion in one hour occurred with the highest concentration of calcium chloride,
0.5M. But with plasmin as activator, peak activation occurred with 0.02M
calcium chloride. This concentration of calcium chloride was used in the
experiment shown in Figure 5.
Here, trypsinogen was incubated with different amounts of plasmin. At
intervals, samples were assayed by hydrolysis of tosylarginine methyl ester.
This substrate was responsive not only to the product, trypsin, but also
to the activator, plasmin, as reflected in the height of the intercepts that
the curves would make with the ordinate axis. The rate at which the assays
rose reflected the rate at which trypsinogen was activated; this was approxi-
mately proportional to the amount of plasmin, as seen on the chart. When
no plasmin was added, no activation occurred, and this shows how good
the limitation of autocatalysis was. That this limitation was not perfect is
revealed by the way some of the curves turned upward as time went on.
And we already know from the preceding chart that trypsin added in
sufficient quantity would cause some activation, even at this concentration
of calcium.
Further results were in accord with the view that the process of activa-
tion depended on the enzymatic function of plasmin since the inactive
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FIG. 4. Comparison of plasmin and trypsin as activators of trypsinogen in the
presence of 0, 0.0008, 0.004, 0.02, 0.1 and 0.5 M added calcium chloride. For each
curve, the highest activation in 1 hour was taken as 100%, and the rest of the values
were plotted accordingly. Figure reproduced from Reference 15, with permission.
precursor, plasminogen, caused no activation. Neither did urokinase. How-
ever, when the same plasminogen was first activated with urokinase, the
resulting plasmin then activated trypsinogen.
Highly purified urokinase (Abbott), in various concentrations up to
75,000 CTA units per ml., failed to activate trypsinogen. Thus, activation
of trypsinogen cannot be predicted merely from the ability to split lysine
esters, which urokinase does well.' Moreover, urokinase activates plas-
minogen rapidly, so its failure to do the same for trypsinogen illustrates
how specific the activator function can be. However, it has been reported
that an arginyl-valine bond is cleaved when urokinase activates plas-
minogen.'M It is not surprising that streptokinase likewise failed to activate
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FiG. 5. Activation of trypsinogen, (200 jig per ml), by various concentrations of
plasmin. At 1, 61, and 121 minutes, samples were assayed for enzymatic activity, in
terms of micromoles of tosylarginine methyl ester hydrolyzed per minute. Figure
reproduced from Reference 15, with permission.
trypsinogen;' for streptokinase is known to be rather inert, except for its
species-specific effect on the activation of plasminogen.
These few results only begin to make contact with a vast and largely
unexplored region. Many investigators anticipate that several activator-
enzymes take part in the clotting process; if so, interesting biochemical
correlations await to be disclosed. In the fibrinolytic system, questions of
specificity have become practically important as well as theoretically fasci-
nating. It is alread-y known that highly purified urokinase has no signifi-
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cant thromboplastic effect;82 it can now be added that urokinase does not
substitute for thrombokinase in the activation of prothrombin, either in
the oxalated or in the fully complemented test mixtures (previously un-
published).
Beyond these, there are other systems, such as those of serum comple-
ment"' and inflammation,'T3M where activation of zymogens is thought to
play a role. Wald has speculated that visual excitation might be another,
and has suggested that enzyme cascades, functioning as biochemical ampli-
fiers, be sought in other phenomena of excitation, whether in receptors,
nerve, muscle, or indeed eggs.' We may conclude that there are at least a
few, and there may be many, "systems of zymogen activation." For the
study of these, the pancreas has provided the classic pattern and some of
the tools.
SUMMARY
It has become increasingly clear that there are systems of zymogen activa-
tion important to physiology and pathology. This encourages the search for
principles and mechanisms common to the various systems.
Trypsin is an activator-enzyme of the classical pancreatic system; but
it can also activate prothrombin, a zymogen of the blood clotting system.
Thrombokinase, a blood enzyme that activates prothrombin, can also acti-
vate chymotrypsinogen, a zymogen from the pancreas. Moreover, thrombo-
kinase can split substituted arginine esters. The primary event in the activa-
tion of chymotrypsinogen by trypsin is the hydrolysis of an arginyl-isoleu-
cine bond; and perhaps this bond is also hydrolyzed by thrombokinase.
Activation of trypsinogen involves hydrolysis of a lysl-isoleucine bond.
The blood enzyme, plasmin (fibrinolysin), which can split lysine esters, is
able to activate trypsinogen. However, urokinase, which also splits lysine
esters, is not able to activate trypsinogen. Nor can urokinase, which acti-
vates plasminogen, substitute for thrombokinase in the activation of pro-
thrombin. Such features of chemical specificity are probably important
biologically.
The pancreatic system is a useful prototype for the study of the blood
clotting and fibrinolytic systems. Serum complement and inflammation are
probably two more systems of zymogen activation. Others may be added
in the future.
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